Literature DB >> 24409059

Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C.

Arvind Reddy1, Elizabeth May1, Murray Ehrinpreis1, Milton Mutchnick1.   

Abstract

AIM: To study the potential association between hepatocellular carcinoma (HCC) in patients with chronic hepatitis C (CHC), cirrhosis and latent hepatitis B (LHB) infection, defined as the absence of detectable serum hepatitis B surface antigen (HBsAg) and the presence of hepatitis B core antibody (HBcAb).
METHODS: This retrospective analysis is comprised of 185 cirrhotic patients with HCC who were hepatitis C virus antibody (HCV Ab) (+) and HBsAg(-) at Wayne State University between 1999 and 2008. From these, 108 patients had HCV polymerase chain reaction confirmation of viremia while the remaining (77) were considered to have CHC on the basis of a positive HCV Ab and the absence of any other cause of liver disease. Controls were drawn from our institutional database from the same time period and consisted of 356 HBsAg(-) age, race and gender matched patients with HCV RNA-confirmed CHC and without evidence of HCC. A subgroup of controls included 118 matched patients with liver cirrhosis. χ² test and t test were used for data analysis.
RESULTS: Seventy-seven percent of patients in all 3 groups were African Americans. Patients with HCC had a significantly higher body mass index (P = 0.03), a higher rate of co-infection with human immunodeficiency virus (HIV) (P = 0.05) and a higher prevalence of alcohol abuse (P = 0.03) than the controls. More patients with HCC had LHB than controls (78% vs 39%, P = 0.01). Sixty three percent of patients with HCC were both hepatitis B surface antigen (HBsAb)(-) and HBcAb(+) compared to 23% of controls (P < 0.01). When compared to cirrhotic controls, the frequency of HBcAb(+) remained higher in patients with HCC (78% vs 45%, P = 0.02). Patients with HCC were more likely to be both HBsAb(-) and HBcAb(+) than the cirrhotic controls (63% vs 28%, P = 0.01). Although not statistically significant, 100% of CHC and HIV co-infected patients with HCC (n = 11) were HBcAb(+) when compared to controls (44%; n = 9).
CONCLUSION: These data suggest that LHB occurs at a significantly increased frequency in patients with CHC and HCC than in patients with CHC without HCC.

Entities:  

Keywords:  Chronic hepatitis C; Hepatitis C virus; Hepatocellular carcinoma; Latent hepatitis B

Mesh:

Substances:

Year:  2013        PMID: 24409059      PMCID: PMC3882405          DOI: 10.3748/wjg.v19.i48.9328

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  21 in total

1.  Impact of occult hepatitis B virus infection on efficacy and prognosis of interferon-alpha therapy for patients with chronic hepatitis C.

Authors:  Izumi Hasegawa; Etsuro Orito; Yasuhito Tanaka; Noboru Hirashima; Kenji Sakakibara; Mayumi Sakurai; Seiji Suzuki; Fuminaka Sugauchi; Tomoyoshi Ohno; Ryuzo Ueda; Masashi Mizokami
Journal:  Liver Int       Date:  2005-04       Impact factor: 5.828

2.  Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients.

Authors:  Giovanni Squadrito; Teresa Pollicino; Irene Cacciola; Gaia Caccamo; Daniela Villari; Tiziana La Masa; Tea Restuccia; Eugenio Cucinotta; Claudio Scisca; Domenico Magazzu; Giovanni Raimondo
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

3.  Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Authors:  Kazuki Ikeda; Hiroyuki Marusawa; Yukio Osaki; Takefumi Nakamura; Naoto Kitajima; Yukitaka Yamashita; Masatoshi Kudo; Tosiya Sato; Tsutomu Chiba
Journal:  Ann Intern Med       Date:  2007-05-01       Impact factor: 25.391

4.  Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.

Authors:  Mikako Obika; Toshiyuki Shinji; Shin-Ichi Fujioka; Ryo Terada; Hiromasa Ryuko; Aye Aye Lwin; Hidenori Shiraha; Norio Koide
Journal:  Intervirology       Date:  2008-03-18       Impact factor: 1.763

5.  Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.

Authors:  Shigeru Adachi; Akitaka Shibuya; Yukiko Miura; Atsuko Takeuchi; Takahide Nakazawa; Katsunori Saigenji
Journal:  Scand J Gastroenterol       Date:  2008       Impact factor: 2.423

6.  [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis].

Authors:  Min Ju Kim; Oh Sang Kwon; Nak So Chung; Seo Young Lee; Hyuk Sang Jung; Dong Kyun Park; Yang Suh Ku; Yu Kyung Kim; Yun Soo Kim; Ju Hyun Kim
Journal:  Korean J Hepatol       Date:  2008-03

7.  Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C.

Authors:  Shunichi Matsuoka; Kazushige Nirei; Akinori Tamura; Hitomi Nakamura; Hiroshi Matsumura; Shuu Oshiro; Yasuo Arakawa; Hiroaki Yamagami; Naohide Tanaka; Mitsuhiko Moriyama
Journal:  Intervirology       Date:  2009-01-07       Impact factor: 1.763

Review 8.  Clinical impact of occult HBV infections.

Authors:  I Chemin; C Trépo
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

9.  Prevalence of low-level hepatitis B viremia in patients with HBV surface antigen-negative hepatocellular carcinoma with and without hepatitis C virus infection in Japan: analysis by COBAS TaqMan real-time PCR.

Authors:  Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; Yasuhiro Hisanaga; Akira Kanamori
Journal:  Intervirology       Date:  2007-04-20       Impact factor: 1.763

10.  Chronic liver disease in Ethiopia: a clinical study with emphasis on identifying common causes.

Authors:  E Tsega; E Nordenfelt; B G Hansson; B Mengesha; J Lindberg
Journal:  Ethiop Med J       Date:  1992-04
View more
  6 in total

1.  Hepatitis B Core Antibody Positivity Associated with Increased Risk of Liver Cancer in Patients with Chronic Hepatitis C: Analysis of a Large Patient Cohort in Hawai'i.

Authors:  Olivia A Collis; Patrycja A Ashley; Li-Hsieh Chen; Kathryn L Pedula; Shelley M Miyashiro; Shellie K Yamashita
Journal:  Hawaii J Health Soc Welf       Date:  2022-05

Review 2.  Role of occult hepatitis B virus infection in chronic hepatitis C.

Authors:  Nicola Coppola; Lorenzo Onorato; Mariantonietta Pisaturo; Margherita Macera; Caterina Sagnelli; Salvatore Martini; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

3.  Activation of the NF-κB pathway as a mechanism of alcohol enhanced progression and metastasis of human hepatocellular carcinoma.

Authors:  Fei Wang; Jin-Lian Yang; Ke-ke Yu; Mei Xu; You-zhi Xu; Li Chen; Yan-min Lu; Hao-shu Fang; Xin-yi Wang; Zhong-qian Hu; Fei-fei Li; Lixin Kan; Jia Luo; Si-Ying Wang
Journal:  Mol Cancer       Date:  2015-01-27       Impact factor: 27.401

Review 4.  HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis.

Authors:  Hao Zhang; Biqing Zhu; He Zhang; Jianxin Liang; Wenting Zeng
Journal:  Biomed Res Int       Date:  2016-11-23       Impact factor: 3.411

5.  Association between anti-HBc positivity and hepatocellular carcinoma in HBsAg-negative subjects with chronic liver disease: A meta-analysis.

Authors:  Nicola Coppola; Lorenzo Onorato; Caterina Sagnelli; Evangelista Sagnelli; Italo F Angelillo
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

Review 6.  Nanotechnology for virus treatment.

Authors:  Jiarong Zhou; Nishta Krishnan; Yao Jiang; Ronnie H Fang; Liangfang Zhang
Journal:  Nano Today       Date:  2020-12-01       Impact factor: 20.722

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.